AGM100® for Acute Respiratory Distress Assessment
Undifferentiated respiratory distress (e.g., COPD exacerbation, pneumonia, heart failure, pulmonary embolism)
CommercialActive
Key Facts
Indication
Undifferentiated respiratory distress (e.g., COPD exacerbation, pneumonia, heart failure, pulmonary embolism)
Phase
Commercial
Status
Active
Company
About MediPines
MediPines, founded in 2014, is a commercial-stage diagnostics company addressing a critical gap in emergency and acute care: the rapid, non-invasive assessment of respiratory impairment. Its AGM100® device delivers actionable data on oxygenation, ventilation, and gas exchange in under two minutes, supporting faster clinical decisions and potentially reducing unnecessary tests and admissions. The company has achieved significant commercial milestones, including a dedicated CPT reimbursement code, positioning it for growth in the expansive respiratory diagnostics market.
View full company profile